Background. A broad, scientific consensus supports the role of cholesterol as a risk factor for coronary heart disease and agrees that lowering cholesterol levels will reduce coronary heart disease incidence. Cost-effectiveness analysis is a potentially powerful method for measuring the benefits to be achieved by expenditures of health care dollars.
C holesterol lowering has generated intense public interest and debate. A variety of interventions are possible, including dietary changes and medications. These interventions can be used as primary prevention, which can either be applied to the entire population or be targeted to high-risk patients, or as secondary prevention for persons with preexisting coronary heart disease. In an era when United States health care costs are escalating at about 3% per year faster than the general inflation rate,' the costs, effectiveness, and cost-effectiveness ratio of each of these alternatives must be addressed.
In September 1990, the National Heart, Lung, and Blood Institute convened a 2-day conference to review the costs and health implications of cholesterol lowering. This report by the conference's organizers and session chairmen draws on the material presented at that conference to summarize the evidence for the benefit of cholesterol reduction, outline the principles of cost-effectiveness analysis, and demonstrate how the accumulated evidence and methods can be used to advance national efforts and programs aimed at cholesterol lowering.
Summary of a conference sponsored by the National Heart, Lung, and Blood Institute, September 17-18, 1990. tDeceased.
Background
The Burden of Coronary Heart Disease Although coronary heart disease remains the single most common cause of death in the United States, over the past two decades coronary heart disease mortality has declined by nearly 50% for persons aged 35-74 years and by somewhat less in the elderly.2 The percent change in each age group is similar in men and women, with men having a threefold higher coronary heart disease death rate through age 65, then a twofold higher rate until age 75, and a 50% higher rate thereafter. 3 African-Americans have higher rates than whites. Age is by far the strongest predictor of coronary heart disease death, with a 100-fold increase between age 40 and 80 years. 3 A decrease in the levels of the major coronary risk factors is believed to have played a major role in the decline in coronary heart disease mortality.2 Reductions in the prevalence of inadequately treated hypertension and cigarette smoking are partly attributable to major governmental intervention, particularly the Surgeon General's Report on Smoking and Health in 1964 and the National High Blood Pressure Education Program of the National Heart, Lung, and Blood Institute beginning in 1974. 4 The prevalence of high blood cholesterol has declined more modestly, but national data from 1960 to 1980 suggest that the decrease is real and associated with a reduction in animal fat consumption and an increase in vegetable oil consumption.2
Scientific Basis for Cholesterol Lowering
There is broad, consistent evidence that lowering elevated blood cholesterol will reduce the risk of sub-sequent coronary heart disease. [5] [6] [7] Animal studies demonstrate reversible relations between dietary fats, serum cholesterol, and arterial lesions resembling human atherosclerosis. Cross-cultural and migrant epidemiological evidence support the impact of dietary animal fat and cholesterol on serum cholesterol and coronary heart disease. Epidemiological studies show that both total and low density lipoprotein (LDL) cholesterol levels are independently associated with coronary heart disease rates. Clinical trials reveal a decrease in the incidence of coronary heart disease in middle-aged men with high blood cholesterol who are assigned to cholesterol-lowering drugs in randomized trials. [8] [9] [10] [11] Other trials have demonstrated slower progression or even regression of atherosclerosis when cholesterol levels are lowered aggressively. [12] [13] [14] [15] There is a continuous and graded relation between serum cholesterol levels and coronary heart disease death, with a fourfold increase in risk from levels of 160 mg/dl to the highest cholesterol values. 16 Because of regression-dilution bias, by which a single cholesterol measurement may misclassify individuals and hence underestimate the strength of the relation between cholesterol and heart disease, the true increase in risk over the full range of cholesterol values is probably closer to sixfold.17'18 Clinical trials have shown that a 1% reduction in serum cholesterol is associated with about a 2% reduction in coronary heart disease incidence,8"19 but the true ratio of benefit, assuming regression-dilution bias, may be 1%: 3%.17
High-Risk and Population-Wide Approaches
The high-risk approach to cholesterol reduction is based on the medical model of preventive medicine, which seeks to help individual patients when they visit a doctor. This approach has the advantage that the intervention can be made appropriate to a motivated individual who may expect personal benefits. Cost-effectiveness may be augmented by directing interventions only at high-risk individuals who will receive the most benefit. Some disadvantages of this approach are that repetitive cholesterol screening of the entire population to identify high-risk individuals is costly and logistically challenging, that the strategy does not prevent persons from becoming high risk in the future, and that it is difficult to change behavior against prevailing fashion.
The population approach, which is not incompatible with a concurrent high-risk approach, is based in the tradition of public health. It tries to change the environment to improve the health of the entire population. This approach would address the cholesterol levels of all adults, including those who are not at highest risk but are at substantial risk, and it would seek to prevent high-risk status before it occurs. However, it may be less effective than the targeted approach in lowering the risk of the highest-risk individuals, and it might influence the eating patterns of low-risk individuals in whom changes may or may not be desirable.
The population approach to primary prevention has been gaining momentum for two decades, whereas the high-risk approach has not been emphasized until recently. One reason for the delay has been that, despite all the evidence noted above, primary prevention trials reduction affects total mortality, and they have not done so. In fact, meta-analysis indicates that reductions in coronary heart disease death may be offset by an increase in noncardiovascular mortality,20 and one recent study found paradoxically higher long-term mortality in persons who were randomized to receive more intensive antilipid and antihypertensive therapy,2' but the potential biological basis of such findings is uncertain. Even assuming that the weight of evidence is correct and that the benefits of cholesterol lowering outweigh the risks in high-risk, middle-aged men, the role for vigorous cholesterol screening and intervention policies in women, in young adults, and in the elderly remains less certain.
Secondary Prevention
Blood cholesterol levels remain a strong predictor of recurrent coronary heart disease and death after a myocardial infarction, and persons with existing disease have a fivefold higher relative risk of a coronary event compared with persons of the same age who do not already have coronary disease.22 Thus, the potential for risk reduction for an individual is far greater in secondary than primary prevention.
The Coronary Drug Project's nicotinic acid group,23 the Stockholm Ischemic Heart Disease Study,24 and the Oslo Diet/Heart Intervention Study25 demonstrated reduced total mortality with cholesterol lowering, with the benefit for total mortality generally appearing later than the benefit for reducing coronary events." Metaanalysis of the short-term results of eight secondary prevention trials" demonstrated a 0.88 relative risk for cardiovascular death and a 0.91 relative risk for allcause mortality in patients randomized to active cholesterol lowering compared with control patients. Other recent trials have shown less progression or even regression of coronary disease when aggressive cholesterol reduction was used as secondary prevention.'2-1' Secondary prevention is also attractive because about 50% of coronary events occur in persons with prior known coronary disease and because treatment is often triggered by a coronary event, when the patient may be more motivated. However, it cannot benefit those persons whose first coronary event is fatal.
Methods Cost-effectiveness analysis is a method to inform policy makers how to maximize the net health benefits to be derived from allocating a fixed amount of scarce resources across alternative potential programs for a target population.26 '27 The analysis compares the costs and clinical outcomes that would be derived by adopting new programs compared with the costs and outcomes resulting from alternative methods of treating those same persons. In doing so, one can determine whether the program under consideration is relatively attractive or unattractive. Each cost-effectiveness ratio specifies the incremental cost that must be spent to achieve an incremental clinical benefit. Programs that both reduce costs and improve clinical outcomes should be adopted because they are better on both grounds. In most cases, however, extra benefits can be achieved only by spendwere not designed to demonstrate that cholesterol ing extra resources.
A decision maker can rank the incremental costeffectiveness ratios, preferentially allocate resources to those programs that have the most attractive (i.e., lowest) ratios, and thus maximize net benefits subject to the constraint of a fixed amount of resources. Costeffectiveness analysis should not be viewed as a method to save costs but rather to show how the maximum number of lives or years of life can be saved per dollar spent.
The benefits of an intervention can be measured by the extension of life and/or a change in the quality of life.26'28 Benefits are often summarized as quality-adjusted years of life, where an additional year of life of full quality is counted as 1 extra year, whereas years of lower quality count less. Aspects of quality of life include the consequences of surviving nonfatal coronary heart disease, restrictive diets, and side effects of medications. These issues have not yet been incorporated into most formal analyses of cholesterol policy.
An incremental cost-effectiveness ratio below about $20,000 per additional quality-adjusted year of life is very attractive. Incremental cost-effectiveness ratios between $20,000 and about $40,000 per additional quality-adjusted year of life are consistent with other currently funded programs, such as hemodialysis or the treatment of mild hypertension with diuretics or propranolol,29 although extrapolation from insurance premiums suggests a higher cutoff.30 Incremental costeffectiveness ratios between about $60,000 and $100,000 per additional quality-adjusted year of life are clearly higher than most currently accepted programs, whereas ratios above $100,000 are generally agreed to be unattractive.
Every medical intervention eventually has diminishing returns, and incremental benefits tend to fall as the intervention's rate, scope, or frequency of use rises. For example, the incremental benefits of Pap smears or mammography fall with increasing frequency of use in specific populations or as the screened populations are expanded to include younger and younger women.31 Similar issues arise in cholesterol policy. The incremental cost-effectiveness of cholesterol-lowering policies among different groups of individuals vary considerably and can guide policy for the allocation of resources.
Future costs are generally less onerous than immediate costs, whereas future benefits are generally less desirable than immediate benefits. Cost-effectiveness analyses usually incorporate this principle by discounting both future costs and future benefits at a rate of about 5% per year. The High-Risk Approach: Health Implications
The guidelines of the National Cholesterol Education Program (NCEP) and the Expert Panel on Detection, Diagnosis, and Management of High Blood Cholesterol in Adults (often called the Adult Treatment Panel or ATP) recommended that blood cholesterol levels be measured at least every 5 years in all adults and more often for those with total cholesterol levels > 200 mg/dl.5
The guidelines classified adults as having high (.240 mg/dl), borderline high (200-239 mg/dl), or desirable (<200 mg/dl) blood cholesterol levels, with the presence of high and borderline high levels to be confirmed LDL cholesterol be measured in persons who are candidates for intensive intervention, and that decisions about intensive lipid-lowering diets and drugs be based on repeated LDL cholesterol levels.
Because the epidemiological evidence for benefit from cholesterol reduction is strongest in middle-aged men, the NCEP-ATP recommended that the physician's judgment and the patient's preferences should influence decisions in other groups, particularly young adults, the elderly, and women. The guidelines suggested that cut points for clinical decisions be riskspecific rather than age-specific, with lower LDL cholesterol cut points for intervention in persons who are otherwise at high risk because of preexisting coronary heart disease or the presence of two or more coronary risk factors, including a low serum level of high density lipoprotein (HDL) cholesterol. Diet was promoted as the primary cholesterol-lowering therapy, but drug treatment was considered potentially appropriate if 6 months of intensive dietary treatment did not lower LDL cholesterol to target levels.
After the NCEP guidelines were published, another set of guidelines for screening and classification of blood lipids was recommended by the United States Preventive Services Task Force. 6 The chief difference of the latter guidelines was that intensive treatment recommendations were based primarily on total cholesterol rather than LDL cholesterol, and that less aggressive recommendations were made for women.
Guidelines have also been recommended by several other North American groups. The Toronto Working Group on Cholesterol Policy7 suggested that cholesterol screening be limited to persons who request it or are at high risk, such as middle-aged men with at least one other risk factor, and their recommended cut points for intensive treatment were considerably higher than those of the NCEP. On the other hand, the guidelines of the Canadian Consensus Conference on Cholesterol32 followed the pattern of the NCEP more closely.
The European Atherosclerosis Society (EAS)33,34 emphasized selective screening and case finding, including risk factor assessment as part of clinical examinations. Both the EAS and the NCEP-ATP guidelines emphasized the multifactorial nature of coronary risk, including cigarette smoking, obesity, and hypertension, and that management decisions be based on the absolute attributable risk rather than on the relative risk. The EAS also felt that risk reduction in women, particularly after the menopause, required greater emphasis, and that lower cholesterol goals should be used in patients with proven coronary heart disease or a positive family history.
The ideal role for screening for low HDL cholesterol levels and for targeting treatment based on HDL cholesterol levels is unclear. Because of the concern about familial hyperlipidemia in children and the high prevalence of hypertriglyceridemia in some populations, further evaluation of these two particular issues is also needed. 33, 34 Using the NCEP-ATP guidelines and the most recent nationally representative serum total cholesterol and lipoprotein data for American adults, it is estimated that 41% of adults would need lipoprotein analysis after initial measurement of total cholesterol, and 36% of all with repeated measurements. It was recommended that adults aged 20-74 years would be candidates for cho-lesterol interventions.35 Based on 1986 population data, these percentages translate into approximately 40 million Americans aged 20-59 years and an additional 24 million Americans aged 60 years or older. A less intensive approach might be appropriate for elderly patients. 5 In the Lipid Research Clinics Follow-Up Study,36'37 there were 308 cardiovascular disease deaths among 8,055 men and nonpregnant women aged 30 years and over who were followed for a mean of 10.1 years. Of these 308 deaths, 85% occurred in participants with two or more nonlipid risk factors, and 72% of the 308 would have qualified for cholesterol-lowering therapy under the NCEP-ATP guidelines. It was estimated that lowering LDL cholesterol to NCEP minimal goal levels might have prevented 68 (22%) of the deaths. All except one of the potentially preventable cardiovascular deaths occurred in persons who were eligible for treatment according to the NCEP-ATP guidelines. By comparison, 44% of patients who did not develop cardiac events or deaths also would have been eligible for treatment. Thus, the potential preventive impact of the NCEP guidelines, when considered for 10 years, resides mainly in patients with multiple risk factors. Although different results might be found for longer time frames, the high mortality in men and women with multiple risk factors suggests that preventive efforts be targeted heavily in this group. In these high-risk patients, efforts should also be aimed at controlling nonlipid coronary risk factors.
The variable impact of cholesterol lowering on the life expectancy of persons with different risk profiles was addressed in an analysis38 that assumed that cholesterol lowering is as effective as predicted by the Framingham Heart Study multiple logistic coefficients that were reported in the early 1970s39,40 and is totally safe. In high-risk persons who smoked 40 cigarettes per day and had a systolic blood pressure of 180 mm Hg and an HDL cholesterol level of 35 mg/dl, a 6.7% dietary cholesterol reduction41 was estimated to increase life expectancy by 3-9 months in women and 0-9 months in men. For low-risk women and men aged 20-80 years who had none of these risk factors, a 6.7% dietary reduction in pretreatment cholesterol levels of 240 mg/dl was estimated to increase life expectancy 2-4 months and 0-2 months, respectively. This analysis has been criticized because it assumed no correlation between serum cholesterol and coronary heart disease death for men after age 65 years, whereas recent analyses show that the relative risk for serum cholesterol may fall with increasing age, but the attributable risk does not decline and may even increase.42 Furthermore, dietary intervention may yield more than a 6.7% reduction in serum cholesterol.
Cholesterol treatment programs may affect quality of life as well as longevity. Potential benefits include avoiding coronary symptoms; potential adverse effects include labeling, the inconvenience of physician visits, dietary changes, and medication side effects. One analy-SiS43 found only small differences in expected quality of life during treatment periods of 10-30 years when a program such as the NCEP-ATP guidelines was compared with no treatment. However, preferences for a given course of action depend on the rankings for a variety of potential positive and negative effects. For example, if patients achieve gratification and satisfac-tion from physician visits and from dietary modifications, intervention programs would be more beneficial for quality of life.
The High-Risk Approach: Economic Implications A broad consensus now exists regarding desirable serum cholesterol levels. Cholesterol levels associated with high risk remain very prevalent in the United States.
High-risk populations can be targeted with dietary or medication programs. In the Women's Health Trial pilot study,44"45 weekly group dietary counseling sessions for 8 weeks followed by biweekly sessions for another 6 months influenced women to reduce their fat intake to about 20% of calories compared with 36% of calories in a randomized control group. 46 This program cost about $551 per person to achieve a 29% relative reduction in the percent of calories from fat. Women in the intervention group spent more time to shop for and prepare food, but over half indicated that they spent no more money for food when on the low-fat diet than when on their prior diets.
The NCEP-ATP explicitly suggested that cholesterol reduction in the elderly should depend on the judgment of the physician and the preferences of the patient.5 It is possible, however, to use epidemiological data35 to project the resources that would be needed if the elderly were to receive medication according to the same guidelines as suggested for younger persons.47 Total estimated expenditures for elderly Americans ranged from about $1.6 billion, if treatment were based on the use of niacin, to about $16 billion, if treatment were based on the use of lovastatin at its highest dose of 80 mg per day. However, the estimated expenses depend on the effectiveness of dietary treatment before medication. For example, the total expenditures from a niacin treatment program were estimated to be about $1.6 billion if diet reduced LDL cholesterol by 15% but to be $2.9 billion if diet reduced these levels by only 5%. Using a consensus panel to describe recommended management patterns and Medicare-allowed charges to estimate the costs for these services, Wittels and col-leagues48 estimated the 5-year cost of coronary heart disease events and procedures. Their analysis suggested that new technologies such as coronary angioplasty have increased the costs of managing coronary disease. As a result, the cost/savings potential of preventive interventions has increased.
Several computer simulation models have combined cost and effectiveness data with epidemiological data from the Framingham Heart Study to estimate the cost-effectiveness of cholesterol reduction.49-52 Each of these models assumes that the full benefits suggested by observational studies for the reduction of the incidence and mortality from coronary heart disease based on cholesterol lowering would occur, and that there would be no increase in mortality rates from noncoronary heart disease causes. All models were also based on total cholesterol levels and assumed that people would be classified accurately. Costs year of life saved in this study37 reflected the use of the least cost-effective lipid-lowering agent at retail prices. 52 Weinstein and Goldman and colleagues5051 used the Coronary Heart Disease Policy Model to examine the relation of age, sex, other risk factors, and prior coronary heart disease on the cost-effectiveness of cholesterol reduction with lovastatin. The Coronary Heart Disease Policy Model is a simulation of the entire United States population between the ages of 35 and 84 years, unlike other risk models that examined disease incidence and then assigned a mean life expectancy and cost for each event to fixed cohorts in each cholesterol range. The analyses were based on studies that demonstrated a 19% reduction in total cholesterol for 20 mg lovastatin and on retail prices that were reduced after the expiration of the patent on lovastatin in 1997.
Lovastatin at 20 mg/day was estimated to be safe and effective53 but relatively costly when given to persons with elevated cholesterol levels for the primary prevention of coronary heart disease except when multiple other risk factors were present.51 For example, among normotensive, nonobese male smokers aged 55-64 years with cholesterol levels >300 mg/dl, the cost per
year of life saved was estimated to be $49,000, but if such persons were also hypertensive (with diastolic blood pressure 95-104 mm Hg) and obese (with weight 110-129% of ideal), it would be $25,000. Cost-effectiveness ratios for women were less favorable than for men. Importantly, lovastatin used for secondary prevention of recurrent events in persons with preexisting coronary heart disease was estimated to have very favorable cost-effectiveness ratios. For men ages 35-64 years and women ages 35-54 years, intervention with 20 mg lovastatin was projected to cost less than the savings from coronary heart disease events that were prevented. For older men and women, cost-effectiveness ratios ranged from $3,300 to $15,000 per year of life saved. This analysis argued strongly for more aggressive cholesterol-lowering treatment of persons with preexisting coronary heart disease.
Schulman, Kinosian, and colleagues52 compared the risk factor profiles. Measurement error in the determination of lipid levels could alter the cost-effectiveness of cholesterol interventions. Weissfeld and colleagues54 modeled NCEP-ATP guidelines to determine the effect of measurement variability on misclassification rates and on the cost-effectiveness of case finding and treatment. Across a 6-12% coefficient of variation of measurement, it was estimated that 92-98% of men below a treatment threshold would be correctly classified, whereas 79-88% of high-risk men above a threshold would be correctly classified. The net effect of measurement error is to worsen the cost-effectiveness ratios of treatment programs by about 10-12%. It is not clear whether the increased investment that would be required to reduce measurement error is warranted.
The validity of simulation models is of concern. Regardless of the specifications of various models, reasonably similar results should be obtained from the same inputs, and a difference should be explained by the models' differing assumptions. The underlying epidemiological assumptions of the models should be validated by data from interventional studies and, ideally, be calibrated and adjusted. 55 The predicted effectiveness and costs also should be prospectively confirmed by demonstration studies.
The cost-effectiveness of intervention among the elderly is uncertain. Although the relative risk associated with cholesterol may be lower in the elderly, their increased overall risk translates into an increase in the attributable risk.56 Conversely, the elderly have a shorter life expectancy from noncoronary diseases, and an individual elderly person may gain fewer additional efficiency of alternative agents in persons with varying years of life from the prevention or postponement of coronary events. Data from intervention trials would be required to determine the benefits of cholesterol reduction in the elderly.
Because both costs and effectiveness vary among medications, estimates of the cost-effectiveness of cholesterol reduction depend on the agent selected. Measurement variability has relatively little effect on the calculated accuracy or cost-effectiveness of cholesterol reduction. Dietary interventions can be efficient. Primary pharmacological prevention can have favorable cost-effectiveness ratios for men with multiple risk factors and even for men without other risk factors when niacin is used. Projections based on total cholesterol may substantially underestimate the benefits of lipid modification if they do not incorporate realistic expectations for the effects of increases in HDL cholesterol. The costs of screening should be incorporated into future analyses. Secondary prevention is so strikingly cost-effective that those with preexisting coronary heart disease appear to deserve separate, more aggressive treatment goals. The Population Approach Whereas targeted cholesterol reduction strategies seek to achieve coronary heart disease reductions in high-risk persons, population strategies aim to lower all persons' cholesterol levels and likelihood of developing coronary heart disease through changes in eating patterns. The population panel of the National Cholesterol Education Program has recommended that healthy Americans obtain less than 10% of total calories from saturated fatty acids and 30% or less from all fat, that they consume less than 300 mg of cholesterol per day, and that total caloric intake be based on energy levels needed to reach or maintain a desirable body weight.57 These dietary principles are intended to apply to persons of all ages, including the elderly and children over the age of 2 years. At present, Americans on average obtain 37% of total calories from fat and about 14% from saturated fat, indicating that at least a 20% average reduction in dietary fat is required to reach this goal.
Reductions in fat consumption have been and may continue to be achieved by reducing the supply of fat in available foods, including meats, dairy products, and processed foods and by reducing the demand for fat by consumers. Future changes in the food supply would require action by the food industry to design, modify, prepare, promote, label, and distribute good-tasting, safe foods that are lower in saturated fatty acids, total fat, and cholesterol. Changes in consumers' demands would require fundamental changes in individual eating behavior, which may be influenced by educational programs, and consistent and standardized food labeling practices that would be enforced by government agencies including the Food and Drug Administration and the U.S. Department of Agriculture.
Encouraging progress has already been made. Within the meat industry, the average thickness of untrimmed external fat on beef, lamb, and pork has been reduced from over 0.25 in. to 0.11, 0.14, and 0.10 in., respectively.58-60 The costs of trimming have been borne both by retailers and by consumers. The potential for even more changes in feeding, selection, and breeding of animal stock. At present, more than 2.07 billion pounds of excess fat on live cattle is being produced annually at an excess cost to consumers estimated to be about $2 billion.61 Thus, healthier meat can be produced at lower cost.
Similar progress is occurring in the dairy and processed food industries, but the challenge has been to maintain good taste, which remains the consumer's highest priority. The industry needs to anticipate and translate national dietary recommendations into product development and positioning, a process that can take 1 or 2 years (personal communication, K. McMahon, PhD, Kraft General Foods). A number of lower-fat food lines and fat-free foods containing fat substitutes have been introduced and successfully marketed in recent years. Current regulatory and legislative food labeling initiatives can impact considerably upon the development of low-fat and nonfat products. Regulated definitions of terms such as "reduced fat" and restrictions on misleading claims such as "no cholesterol" in high-fat foods are needed for consumers to make reasoned choices. A Federal Trade Commission report demonstrated that food labeling can be an effective educational strategy in hard-to-reach population groups, and Congress has legislated food labeling. Labeling of high-fiber cereals may have led to desirable changes in cereal choices by nonwhite Americans. 62 Intensive community-based programs designed to promote healthier dietary behaviors have also resulted in small but consistent average changes across the targeted population. Data from North Karelia in Fin-land63 showed that a community-wide intervention program involving both community and physician education lowered serum cholesterol levels by 3% in men and 1% in women after 10 years. In the Stanford Three-Community Study64 and the Stanford Five-Community Study,65 cholesterol reductions of 3% and 2%, respectively, were achieved. These programs also achieved reductions in other coronary heart disease risk factors, including diastolic blood pressure and smoking.
Although the wisdom of interventions in children has been questioned,66 interventions in school-age children have also been modestly effective for lowering serum cholesterol levels. Such programs resulted in a 2% reduction in cholesterol levels in Finnish seventh-and eighth-grade students,67 a 4% reduction in Norwegian fifthto seventh-graders,'8 an 8.5-mg/dl reduction in Westchester County, N.Y., fourthto eighth-graders,69 and a 5.0-mg/dl reduction in Bronx, N.Y. fourthto eighth-graders. 69 Some analyses suggest that population-wide reductions in cholesterol levels may have accounted for as much as 25-30% of the nationwide decline in coronary mortality.70 However, Browner et a171 have estimated that if Americans further lowered their fat consumption to the recommended 30% level, there would be a 3-mg/dl serum cholesterol reduction for each 1% change in the percent of total calories consumed as saturated fat. Using published data,72,73 they projected about a 5% decrease in coronary heart disease mortality in women and older men and about a 15% decrease in younger and middle-aged men. When they included projected reductions in cancer mortality, life expectancy important reductions in internal fat exists through was estimated to be prolonged by 3 months in women and 4 months in men; about 80% of the projected benefit was in persons over age 65 years. If cholesterol reduction has adverse effects on noncoronary mortality, the net benefits would be lower.
The costs of community-wide intervention programs are difficult to estimate. Estimates There is no reason why the United States must choose between a purely targeted and a purely population-wide approach to the reduction of serum cholesterol. Evidence regarding the effectiveness76 and cost-effectiveness75 of population-wide approaches strongly supports their inclusion in any comprehensive American program to reduce cholesterol and coronary heart disease.
Conclusions
Randomized controlled trials have demonstrated the benefit of cholesterol reduction as primary prevention to reduce coronary heart disease in middle-aged men. There is no clinical trial evidence that primary prevention will reduce overall mortality, but secondary prevention trials in men with a prior myocardial infarction have shown a reduction in recurrent coronary heart disease events that is subsequently associated with a reduction in total mortality.
Cost-Effectiveness Methodology: Strengths and Limitations
Cost-effectiveness analysis is a potentially powerful analytic tool to guide the allocation of scarce resources. Cost-effectiveness models of the implications of cholesterol reduction have routinely assumed that persons who reduce their cholesterol will have the full benefit suggested by epidemiological studies, although without correction for regression-dilution bias, that there will be no major side effects from cholesterol reduction, and that there will be no changes in the rates of noncoronary morbidity and mortality in persons whose cholesterol levels are reduced.
Cost-effectiveness models are built from a set of assumptions derived from empirical evidence from a variety of sources. To the greatest extent possible, cost-effectiveness models should be built on firm data from prospective epidemiological studies. Randomized controlled trials are important to document benefits, but their selected enrollees are not ideal for estimating the precise expected lifetime population-wide impact. Sometimes the data and modeling issues are valid and precise representations of the real world, and other models are no more or less accurate than the empirical evidence from which they are derived.
Published analyses must include sufficient method- 
Cost-Effectiveness and Health Policy
Because of the prevalence of elevated cholesterol levels and of coronary heart disease and the major costs that could be incurred by nationwide prevention and treatment programs, considerations of cost-effectiveness are clearly relevant to the issue of cholesterol reduction and the planning of national cholesterol programs. Although individual physicians are uncomfortable with the concept that cost considerations should guide their treatment of an individual patient, cost must be an important issue in setting national health priorities. Thus, cost-effectiveness analysis should be incorporated into the evolution and implementation of future national cholesterol guidelines.
Cost and quality-of-life considerations should be incorporated into future trials of cholesterol reduction. Quality-of-life measures must be quantitative and should permit the calculation of quality-adjusted life expectancy. Such future trials should concentrate on those persons who have not been the subject of recent randomized trialspersons with prevalent coronary heart disease, women, the elderly, and younger persons with elevated cholesterol levels.
In considering cost and cost-effectiveness in the development of the treatment guidelines, a balance must be found between precision and simplicity if rational guidelines are to be set and followed widely. Such guidelines should consider quality of life as well as longevity.
Although there has not yet been a comprehensive cost-effectiveness analysis of the guidelines of the NCEP-ATP, their guidelines are reasonably consistent with many of the cost and cost-effectiveness projections. Diet therapy should be the cornerstone to any national program, and it should be encouraged for all Americans. Population-wide educational programs that result in modest cholesterol reductions appear very attractive because their costs are low compared with their projected benefits. Medications for cholesterol reduction are especially cost-effective when used as secondary prevention in persons with prior coronary disease because, in such persons, the risk of a second coronary event is higher than the risk of a first coronary event times they are more of an educated guess. Simulation even in persons with multiple risk factors. The costeffectiveness of medications for primary prevention depends on the medication itself and on the risk factor profile of the individual. Cholesterol reduction for primary prevention becomes progressively more favorable from a cost-effectiveness standpoint as the individual has additional risk factors. The cost of medications is a key issue, and medications that yield greater cholesterol reductions per dollar are generally more cost-effective. For example, niacin, which is the least expensive drug, may approach a reasonable cost-effectiveness ratio even in persons without additional risk factors, especially if it has additional benefit by raising the HDL cholesterol levels. Cost-effectiveness analyses can highlight situations such as primary prevention in the absence of multiple risk factors, in which reductions in the cost of therapy should be an important goal so that clinically effective interventions can be made more costeffective.
Cost-effectiveness analysis also permits the comparison of cholesterol-lowering programs to other health programs,77,78 and these comparisons should help guide health policy. Cost-effectiveness and economic considerations should be integrated into the development of a national health policy for cardiovascular diseases and for a wide variety of other national health issues.
